研究单位：[1]Teligene US[2]OPN Healthcare, Inc.,Glendale,California,United States,91203[3]University Cancer & Blood Center,Athens,Georgia,United States,30607[4]Baptist Health,Louisville,Kentucky,United States,40223[5]University of Maryland Medical Center,Baltimore,Maryland,United States,21201[6]FirstHealth Cancer Center,Pinehurst,North Carolina,United States,28374[7]The University of Texas- MD Anderson Cancer Center,Houston,Texas,United States,77030[8]The First Affiliated Hospital of Bengbu Medical College,Bengbu,Anhui,China,230000[9]Cancer Hospital Chinese Academy of Medical Sciences,Beijing,Beijing,China,100021[10]Beijing Cancer Hospital,Beijing,Beijing,China,100142[11]Peking Union Medical College Hospital,Beijing,Beijing,China,100730[12]Beijing Chest Hospital,Beijing,Beijing,China,101125[13]The Affiliated Cancer Hospital of Chongqin University,Chongqing,Chongqing,China,400044[14]The First Affiliated Hospital of Guangzhou Medical University,Guangzhou,Guangdong,China,510230[15]Harbin Medical University Cancer Hospital,Harbin,Heilongjiang,China,150086[16]Henan Cancer Hospital,Zhengzhou,Henan,China,450003[17]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China,450052[18]Wuhan Union Hospital of China,Wuhan,Hubei,China,430000[19]Hunan Cancer Hospital,Changsha,Hunan,China,410006[20]Jiangsu Province Hospital,Nanjing,Jiangsu,China,210029[21]Jilin Cancer Hospital,Changchun,Jilin,China,130012[22]The First Affiliated Hospital of China Medical University,Shengyang,Liaoning,China,830000[23]Linyi Cancer Hospital,Linyi,Shangdong,China,276001[24]Shanghai Chest Hospital,Shanghai,Shanghai,China,200052[25]Shanghai Pulmonary Hospital,Shanghai,Shanghai,China,200437[26]Sichuan Cancer Hospital,Chengdu,Sichuan,China,610044[27]Zhejiang Cancer Hospital,Hangzhou,Zhejiang,China,310022
This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)
